Patents Issued in December 6, 2018
  • Publication number: 20180344632
    Abstract: A tissue repair fibrous membrane, preparation method and application thereof, and tissue repair product. The tissue repair fibrous membrane is formed by interweaving fiber filaments having a diameter of 10 nm to 100 ?m, and has pore structures formed by interweaving between the fiber filaments. The fiber filaments have concave structures, and have annular convex structures thereon in the radial direction of the filaments.
    Type: Application
    Filed: November 25, 2016
    Publication date: December 6, 2018
    Inventors: Kunxue DENG, Yuyu YUAN
  • Publication number: 20180344633
    Abstract: The present invention provides a salivator that is in a form for use in the mouth (a form for intraoral use), or in a form for use by oral administration (a form for oral administration). The salivator can be prepared by using enzymatically modified isoquercitrin, or a combination of enzyme-modified isoquercitrin and a thickening polysaccharide. The present invention further provides an additive that is useful for preparing an oral composition (a food or beverage, a pharmaceutical product for oral administration)(an additive for an oral composition) and that can impart at least one effect selected from the group consisting of a salivation-promoting effect, a deglutition-improving effect (swallowing-assisting effect), and a mastication-improving effect (chewing-assisting effect) to the oral composition. The additive can be prepared by using a combination of enzymatically modified isoquercitrin and a thickening polysaccharide.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 6, 2018
    Applicant: SAN-EI GEN F.F.I., INC.
    Inventors: Hiroyuki SATO, Makoto NAKAUMA, Akira IKEGAMI, Takahiro FUNAMI, Hideyuki ORIKOSHI
  • Publication number: 20180344634
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 6, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Publication number: 20180344635
    Abstract: An invention that allows you to enjoy different drinks instantaneously by adding a cubed tablet to liquid. This allows for spontaneous enjoyment of your favorite beverage drink. The drink can be dissolved in hot or cold water with ease by dropping one cube in a cup and stir. This can be used for coffee drinks, chocolate drinks, teas, and instant juices.
    Type: Application
    Filed: June 6, 2017
    Publication date: December 6, 2018
    Inventor: Chad Galyean
  • Publication number: 20180344636
    Abstract: A method for manufacturing an anti-vaginitis suppository includes: immersing a carbonaceous material in an aqueous solution containing an active ingredient salt; thermally drying the aqueous solution at 60-500° C. to attach an agglomerate of the active ingredient salt to the carbonaceous material; pyrolyzing the agglomerate at 200-1000° C. to convert into a particle of the active ingredient attached to the carbonaceous material; mixing the carbonaceous material and the particle thereon with a matrix to obtain a mixture; and solidifying the mixture to form the suppository.
    Type: Application
    Filed: June 6, 2017
    Publication date: December 6, 2018
    Applicant: Feng Chia University
    Inventor: Tse-Hao KO
  • Publication number: 20180344637
    Abstract: A composition for targeted delivery of a therapeutic agent is provided herein, the composition including poly(styrene-co-maleic acid) (SMA) covalently conjugated to hyaluronic acid (HA). The HA-SMA composition optionally forms a micelle for targeted delivery of a therapeutic agent. Also provided herein is a method of treating a condition by administering a therapeutically-effective amount of a composition including HA-SMA conjugate and a non-covalently associated therapeutic agent, optionally further including curcumin difluorinated (CDF) or other therapeutic agent.
    Type: Application
    Filed: May 16, 2016
    Publication date: December 6, 2018
    Inventor: Arun K. Iyer
  • Publication number: 20180344638
    Abstract: Disclosed is a method for preparing a composition for an anionic drug delivery with increased production yield, comprising forming nanoparticles by using electrostatic interaction of an anionic drug and a cationic compound in an aqueous phase; and incorporating the nanoparticles into polymeric micelles comprising an amphiphilic polymer and optionally a polylactic acid salt to increase the electrostatic interaction and hydrophobic binding, thereby increasing the entrapment efficiency of the anionic drug in the formulation.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 6, 2018
    Inventors: Hye Yeong NAM, Sang-Hee KIM, Min-Hyo SEO, Ji-Yeon SON
  • Publication number: 20180344639
    Abstract: The present invention provides a composition and method for targeting hypoxic tumor areas for detection or treatment or a treatment adjuvant for cancer. Specifically, a hypoxia targeting moiety is conjugated to a polymeric micelle containing imaging agents, therapeutic agents, or therapeutic adjuvants.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 6, 2018
    Inventors: Brij P. Giri, Kristina Gregg, Pritam Singh, Dinesh J. Dagli, Anshu Giri
  • Publication number: 20180344640
    Abstract: The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: EXELTIS USA DERMATOLOGY, INC.
    Inventors: Christopher N. HENSBY, Mats SILVANDER
  • Publication number: 20180344641
    Abstract: The present disclosure is directed to methods of producing monosized protocells from monosized mesoporous silica nanoparticles (mMSNPs) and their use for targeted drug delivery formulations and systems and for biomedical applications. The present disclosure is also directed in part to a multilamellar or unilamellar protocell vaccine to deliver full length viral protein and/or plasmid encoded viral protein to antigen presenting cells (APCs) in order to induce an immunogenic response to a virus.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 6, 2018
    Inventors: C. Jeffrey Brinker, Paul N. Durfee, Jason Townson, Yu-Shen Lin, Stanley Shihyao Chou, Jacob Erstling
  • Publication number: 20180344642
    Abstract: A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1? and/or HIF-2? includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: December 6, 2018
    Inventors: Yang LIU, Yin WANG, Yan LIU, Christopher BAILEY, Pan ZHENG
  • Publication number: 20180344643
    Abstract: The present disclosure relates to a method of delivering target materials into extracellular vesicles including exposing the target materials and the extracellular vesicles to extracorporeal shockwaves, a method of preparing target material-introduced extracellular vesicles, extracellular vesicles prepared by the method, drug delivery vehicles including extracellular vesicles, and a method of delivering target materials into cells. The present disclosure exposes extracellular vesicles derived from natural organisms such as animal cells, plant cells, and microorganisms including bacteria and eukaryotic bacteria as well as artificially produced extracellular vesicles to extracorporeal shockwaves extracellularly. Thus, the high-level energy extracorporeal shockwaves can be used to deliver the target material into the extracellular vesicle efficiently. When treating with extracorporeal shockwaves, the ability of target material-introduced extracellular vesicles to incorporate into target cells also increases.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Inventors: Kihwan Kwon, Jihwa Chung, Kyounghwa Kim
  • Publication number: 20180344644
    Abstract: The present invention provides improved stable liposomal formulations and method of preparation thereof. The liposomal formulations include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane, wherein the taxane is docetaxel or a derivative thereof. The liposomal formulations have improved stability and extended shelf-life. The present invention also provides pharmaceutical compositions comprising a liposomal formulation for the treatment of cancer.
    Type: Application
    Filed: September 21, 2016
    Publication date: December 6, 2018
    Inventors: Satheesh Podaralla, Tsz Chung Lai, Baohua Yue
  • Publication number: 20180344645
    Abstract: The present invention generally relates to preparation methods of nanoparticles or nanocrystals of narrowly distributed particle sizes of a poorly water soluble material. In particular, this invention is an effective integration of the bottom-up and top-down preparation methods of nanoparticles and nanocrystals of a poorly water soluble material or active pharmaceutical ingredient into a single process, which affords an efficient and simple process with a product of improved delivery and therapeutic effects.
    Type: Application
    Filed: June 6, 2018
    Publication date: December 6, 2018
    Applicant: Purdue Research Foundation
    Inventors: Tonglei Li, Wei Gao
  • Publication number: 20180344646
    Abstract: Amorphous dispersion granules comprising an amorphous solid solution of an active pharmaceutical ingredient and a dispersing polymer, and deposited thereon a substrate comprising at least one first tableting agent, as well as oral dosage forms comprising the amorphous dispersion granules of the invention, including pharmaceutically acceptable tablets comprising the amorphous dispersion granules of the invention, and methods of preparing amorphous dispersion granules and pharmaceutically acceptable tablets manufactured therefrom.
    Type: Application
    Filed: November 14, 2016
    Publication date: December 6, 2018
    Applicant: PATHEON DEVELOPMENT SERVICES INC.
    Inventors: Sanjay Konagurthu, Thomas REYNOLDS, Marshall CREW
  • Publication number: 20180344647
    Abstract: The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 6, 2018
    Inventors: Georg BOECK, Kerstin Julia FRANK, Venkata VOLETI, Tracy WILLIAMSON
  • Publication number: 20180344648
    Abstract: A pharmaceutical composition comprising clobazam or its pharmaceutically acceptable salt(s) or solvate(s) thereof of defined particle size and one or more pharmaceutically acceptable excipients is described. A method for preparing the composition is also described.
    Type: Application
    Filed: November 29, 2016
    Publication date: December 6, 2018
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Vipan DHALL, Aravind KERUDI, Tapan BUCH, Ajay SAV
  • Publication number: 20180344649
    Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
    Type: Application
    Filed: September 28, 2016
    Publication date: December 6, 2018
    Inventors: Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
  • Publication number: 20180344650
    Abstract: Disclosed herein is a core-shell composite material comprising: a core optionally comprising an active ingredient compound; a shell structure comprising at least two alternating layers; the alternating layers being a protein layer and a polyphenol layer; and optionally a polyelectrolyte layer interfacing said core and said shell structure, said polyelectrolyte layer being disposed adjacent to said protein layer or said polyphenol layer, wherein said shell structure is selected to be resistant to degradation under gastric conditions but is degradable by one or more intestinal enzymes. In a preferred embodiment the protein is bovine serum albumin (BSA) or pepsin, the polyphenol layer is tannin or tannic acid, and the shell structure is degradable by pepsin.
    Type: Application
    Filed: October 26, 2016
    Publication date: December 6, 2018
    Inventors: Harjinder SINGH, Brendan HAIGH, Nicole ROY, Maxim KIRYUKHIN, Maria ANTIPINA, Marina NOVOSELOVA, Gleb SUKHORUKOV
  • Publication number: 20180344651
    Abstract: Described herein are abuse deterrent oral pharmaceutical compositions, methods for making the same, and methods of treatment using such compositions. In particular, oral pharmaceutical compositions that mitigate the risk of overingestion of one or more active pharmaceutical ingredients are described.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 6, 2018
    Inventors: Justin HUGHEY, Jason VAUGHN
  • Publication number: 20180344652
    Abstract: The present disclosure relates to a composition of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, a preferred composition comprises poly-L-lysine and a gellan gum, preferably a methacrylate gellan gum. The present subject-matter further relates to methods for generating composition of the present disclosure and to uses of a mixture according to the disclosure for biomedical applications such as cellular and acellular systems for tissue engineering and regenerative medicine applications or as drug delivery systems, for the treatment of several diseases namely diabetes mellitus.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Inventors: Sílvia CRISTINA ARAÚJO VIEIRA, Joaquim MIGUEL ANTUNES DE OLIVEIRA, Rui LUÍS GONÇALVES DOS REIS, Joana CATARINA DA SILVA CORREIA
  • Publication number: 20180344653
    Abstract: The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
    Type: Application
    Filed: January 24, 2018
    Publication date: December 6, 2018
    Inventors: Harinder Singh, Shavej Ahmad, Romi B. Singh
  • Publication number: 20180344654
    Abstract: A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Inventors: Monty Liong, Jie Lu, Fuyuhiko Tamanoi, Jeffrey I. Zink, Andre E. Nel
  • Publication number: 20180344655
    Abstract: Nanoparticle compositions including one or more active agents, and strategies for enhanced delivery of the active agents, are provided. In preferred embodiments, the nanoparticles are composed of block copolymers of one or more hydrophobic polymers that form the core, and a hyperbranched polymer that forms a shell or corona. In some embodiments, the particles include an acid-sensitive, poly(amine-co-ester) (PACE) that can increase release of the active agent in acidic environments, for example within endosomes. The compositions can include one or more targeting moieties. Preferred targeting moieties include adenosine agonists and pHLIP which can enhance delivery to tumor cells. Methods of using the compositions to treat diseases and disorders of the central nervous system, for example, brain cancers such as glioma, are also provided.
    Type: Application
    Filed: May 11, 2016
    Publication date: December 6, 2018
    Inventors: William M. Saltzman, Yang Deng, Jennifer Saucier-Sawyer, Alice Gaudin, Young-Eun Seo, Eric Song
  • Publication number: 20180344656
    Abstract: The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.
    Type: Application
    Filed: May 24, 2018
    Publication date: December 6, 2018
    Inventors: Justin Hanes, Michelle R. Dawson, Denis Wirtz, Jie Fu, Eric M. Krauland
  • Publication number: 20180344657
    Abstract: The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: KATHLEEN EMILY-ANN HALASZ, YASHWANT V. PATHAK, VIJAYKUMAR BHADABHAI SUTARIYA
  • Publication number: 20180344658
    Abstract: The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Inventors: Steven DE VLEESCHOUWER, Matthias VAN WOENSEL, Karim AMIGHI, Nathalie WAUTHOZ, Rémi ROSIERE
  • Publication number: 20180344659
    Abstract: A new method of targeted drug administration to wounds (surgical or traumatic), intrasite (IS), offers advantages in treatment efficacy and safety over traditional routes of administration. A novel method of dosing IS medications based on wound surface area provides the parameters for safe and effective dosing, a necessary advance for any FDA approval. Large IS doses increase risk of toxicity from impurities allowed in drugs given by other routes. Methods are presented for ultrapurification, particularly of endotoxins. Methods are presented for sterile delivery to the wound, to prevent aerosolization, and to homogenize application. Pharmacodynamic parameters make certain drugs advantageous as IS agents, including slow trans-wound surface diffusion, protein binding, and limited local tissue toxicity. Vancomycin is a prototypical drug with these features and is therefore very useful as an IS medication.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 6, 2018
    Applicant: HKL Medical, LLC
    Inventors: Terrence Fletcher Holekamp, Lawrence Gerard Lenke, Michael Patrick Kelly
  • Publication number: 20180344660
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 6, 2018
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20180344661
    Abstract: The present invention provides cannabis oil compositions, including cannabis oil compositions containing vitamin E, and methods for preparing the cannabis oil compositions. In some embodiments, the invention provides a method for preparing a cannabis oil composition comprising eluting cannabinoids from cannabis plant material with a solvent to produce an eluate; filtering the eluate with a filter to produce a filtrate; evaporating the solvent from the filtrate with a distiller to produce a distillate; and purging the distillate under conditions sufficient to remove residual solvent. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract. Blended cannabis oil compositions containing mixtures of cannabis oil preparations are also described.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Applicant: Constance Therapeutics, Inc.
    Inventors: Constance FINLEY, Haley POOLE BESTWICK
  • Publication number: 20180344662
    Abstract: Veterinary compositions and methods for production and use. A method of treating bees at or near a bee hive with a first and/or second veterinary composition is described including administering to bees a veterinary composition comprising at least cannabinoid, and/or at least two non-cannabinoid cannabis compounds, with or without a carrier, thereby enhancing bees performance.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 6, 2018
    Applicant: Canabuzz-Med
    Inventors: Aharon M. EYAL, Netta LIN-COHEN, Youval LIN, Meir ARIEL
  • Publication number: 20180344663
    Abstract: A cannabis based therapeutic product for treatment of chronic pain produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, separating the cannabis compounds from the oils using high pressure liquid chromatography, flash chromatography, or similar techniques, and processing selected cannabis compound formulations into a pill, tablet, liquid, or other form suitable for administration as a therapeutic product for treatment of chronic pain, optionally with the further step of enriching the product with a formulation comprising at least 1% by weight purified -myrcene, prior to processing into a final product.
    Type: Application
    Filed: April 13, 2018
    Publication date: December 6, 2018
    Inventors: Michael Viet Thang Vu, Larry Nelson Thacker, JR., Alex Thacker, Nelson Miguel Ricardo Martinez, Michael William Bell
  • Publication number: 20180344664
    Abstract: The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Inventors: Geena Malhotra, Kalpana Joshi
  • Publication number: 20180344665
    Abstract: Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 6, 2018
    Inventors: Jason C. Isenburg, Matthew F. Ogle
  • Publication number: 20180344666
    Abstract: The present disclosure provides a lipid emulsion formulation comprising vitamin K, and methods of treating pharma toxicity.
    Type: Application
    Filed: November 11, 2016
    Publication date: December 6, 2018
    Inventors: Guy WEINBERG, Israel RUBENSTEIN
  • Publication number: 20180344667
    Abstract: The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Inventors: Guy M. Miller, Viktoria Kheifets
  • Publication number: 20180344668
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Application
    Filed: March 30, 2018
    Publication date: December 6, 2018
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Publication number: 20180344669
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Application
    Filed: December 28, 2017
    Publication date: December 6, 2018
    Applicant: Shire LLC
    Inventors: Amir Shojaei, Stephanie Read, Richard A. Couch, Paul Hodgkins
  • Publication number: 20180344670
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Publication number: 20180344671
    Abstract: The present invention relates to compositions of cysteamine or a derivative thereof for use in the treatment or prophylaxis or a disease or condition associated with neutrophil elastase activity. The compositions can be administered, e.g., by inhalation, intravenously, or topically, as appropriate.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: Deborah O'Neil, Douglas Fraser-Pitt
  • Publication number: 20180344672
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Kenji EGUSA, Takuma KATAYAMA, Kazutoshi YOKOYAMA, Remko Alexander BAKKER, Ngai Hang Victor CHONG, Joerg RIPPMANN
  • Publication number: 20180344673
    Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventor: David A. Dill
  • Publication number: 20180344674
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Inventor: David A. Dill
  • Publication number: 20180344675
    Abstract: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.
    Type: Application
    Filed: April 26, 2018
    Publication date: December 6, 2018
    Inventor: Bramah N. Singh
  • Publication number: 20180344676
    Abstract: This disclosure relates to natural topical and analgesic pain relief and anti-inflammation compositions and methods to reduce pain and inflammation. This disclosure also relates to the use of cannabinoid compounds in hydrophilic compositions comprised of synthetic and natural plant extract compounds that are multifunctional TRPM8 ion channel agonists, TRPA1 and TRPV1 ion channel antagonists, CGRP antagonists, COX-2 inhibitors and CB1 and CB2 antagonists. In particular, this disclosure relates to a topical analgesic composition comprising at least one synthetic or natural plant extract TRPM8 agonist, at least one synthetic or natural plant extract is a TRPA1 antagonist, and fixed plant seed oil containing Omega-3 fatty acids TRPV1 antagonists and a carrier.
    Type: Application
    Filed: September 29, 2016
    Publication date: December 6, 2018
    Inventor: George Edward Hoag
  • Publication number: 20180344677
    Abstract: The invention provides a food supplement comprising chromium and the five amino acids leucine, isoleucine, valine, threonine and lysine, wherein leucine, isoleucine, valine, threonine and lysine are the only amino acids present in the food supplement, and wherein the sum content of the five amino acids is from 1.75 to 3.5 g per dose of the food supplement, and wherein the content of chromium is from 4.5 to 61 ?g per dose of the food supplement. A food composition comprising the food supplement, as well as the five amino acids for use in a method of treating, controlling or preventing diseases or conditions related to the metabolic syndrome, treating or controlling diabetes, treating, controlling or preventing obesity, promoting satiety, promoting weight loss, or promoting maintenance of a healthy bodyweight, by lowering postprandial glycaemia, and preferably also by lowering postprandial insulin secretion, are also provided.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 6, 2018
    Inventors: Rickard ÖSTE, Elin ÖSTMAN, Inger BJÖRCK
  • Publication number: 20180344678
    Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.
    Type: Application
    Filed: May 1, 2018
    Publication date: December 6, 2018
    Applicant: Burke Medical Research Institute
    Inventors: Rajiv R. RATAN, Saravanan KARUPPAGOUNDER, Thomas I. BRADSHAW
  • Publication number: 20180344679
    Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
    Type: Application
    Filed: June 12, 2018
    Publication date: December 6, 2018
    Inventors: Lili Feng, Sven Erik Godtfredsen, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Bin Hu, Yugang Liu, Thomas J. Blacklock, Piotr Henryk Karpinski
  • Publication number: 20180344680
    Abstract: Compositions and methods are provided for treating, ameliorating, and preventing diabetes-related skin ulcers in a mammalian subject comprising administering to the subject an effective amount of an NRF2 activating agent.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 6, 2018
    Inventors: Donna D. Zhang, Georg T. Wondrak
  • Publication number: 20180344681
    Abstract: A iontophoresis method (700) is described for delivering vitamin C through the skin of a biological subject, the method comprising applying (702) a selected current profile, either continuous direct current or pulsed current or a combination of both to a biological subject. A iontophoresis composition is further described, comprising one or more of vitamin C, vitamin C derivatives, ions of vitamin C and ions of vitamin C derivatives and further comprising a silicon material and water. A ionotophoresis kit for carrying out the iontophoresis method is also disclosed. The application further describes a iontophoresis device comprising an electrode assembly and circuitry configured to concurrently generate a continuous direct current stimulus and a pulsed current stimulus; a corresponding iontophoresis method for delivering a cosmetic composition to a biological subject is also disclosed.
    Type: Application
    Filed: December 6, 2016
    Publication date: December 6, 2018
    Applicant: L'OREAL
    Inventors: Jennyfer CAZARES DELGADILLO, Thi Hong Lien PLANARD-LUONG